JPRN-UMIN000051797尚未招募Unknown
Systemic therapy for Unresectable Hepatocellular Carcinoma: Therapeutic Effectiveness by Treatment Modality and Optimal Drug Use Order - Systemic therapy for unresectable HCC
Japanese Red Cross Society Himeji Hospital0 个研究点目标入组 5,000 人开始时间: 2023年8月2日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who refuse to use clinical data (blood samples, imaging, pathology).
研究者
相似试验
尚未招募
不适用
Choices of therapeutic strategies for hepatocellular carcinoma (HCC)C22.0Liver cell carcinomaDRKS00025099Chirurgische Klinik, Universitätsmedizin Mannheim200
进行中（未招募）
不适用
Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001)Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Rap-001) - treatment of HCC with rapamyciAdvanced hepatocellular carcinoma (HCC)EUCTR2004-002834-20-ATniversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie30
进行中（未招募）
不适用
Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) - RAD-09advanced hepatocellular carcinoma (HCC) with portal vein thrombosisMedDRA version: 9.1Level: LLTClassification code 10024662MedDRA version: 9.1Level: PTClassification code 10019713EUCTR2009-016475-29-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
不适用
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINEPER-039-01SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
3 期
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCCHepatocellular CarcinomaNCT01229839Sun Yat-sen University668